Print
|
Close
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Active:
No
Cancer Type:
Breast Cancer
Gynecologic Cancers
Ovarian Cancer
Primary Peritoneal Cancer
NCT ID:
NCT02657889
Trial Phases:
Phase I
Phase II
Protocol IDs:
3000-PN162-01-001 (primary)
NCI-2016-00219
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Tesaro Inc
NCI Full Details:
http://clinicaltrials.gov/show/NCT02657889
Summary
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with
niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic
triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.